Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Dosage regimen for administrating a CD19×CD3 bispecific antibody to patients at risk for potential adverse effects

Dosage regimen for administrating a CD19×CD3 bispecific antibody to patients at risk for potential adverse effects

US Patent 10191034 · Granted Jan 29, 2019

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Prevention of adverse effects caused by CD3 specific binding domains2023
Dosage regimen for administering a CD19xCD3 bispecific antibody to patients at r2023
Anti-leukocyte adhesion for the mitigation of potential adverse events caused by2021
Means and methods for treating DLBCL2020
Dosage regimen for administering a CD19XCD3 bispecific antibody2020
Prevention of adverse effects caused by CD3 specific binding domains2018
Anti-leukocyte adhesion for the mitigation of potential adverse events caused by2017
PPS for the prevention of potential adverse effects caused by CD3 specific bindi2016
Means and methods for treating DLBCL2015
Dosage regimen for administering a CD19XCD3 bispecific antibody2014